NVZMF News and Press, Novonesis AS - Class B From 07/07/25

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and...

2025-06-01 07:01:45 ET Summary Novonesis is a global market leader in enzymes and biosolutions, offering defensive growth and resilience across essential industries like food, agriculture, and household care. The company has delivered strong organic growth, repeatedly raising guid...

2025-05-11 10:32:06 ET Novonesis A/S (NVZMF) Q1 2025 Earnings Conference Call May 08, 2025, 03:00 AM ET Company Participants Tobias Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehmann - Chief Financial Officer Amy B...

2025-05-09 04:59:03 ET More on Novonesis A/S Novonesis A/S (NVZMF) Q4 2024 Earnings Call Transcript Novonesis A/S 2024 Q4 - Results - Earnings Call Presentation Novonesis A/S reports FY results Historical earnings data for Novonesis A/S Dividend score...

COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both...

2025-02-28 17:37:54 ET Summary DSM-Firmenich's FY 2024 results show promising growth and profitability, with 6% organic sales growth and 19% adjusted EBITDA increase, despite a challenging macroeconomic environment. The company is making progress on the promised synergies, targeti...

2025-02-26 08:39:34 ET Novonesis A/S (NVZMF) Q4 2024 Earnings Conference Call February 26, 2025 03:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehmann - Chief Financial Off...

2025-02-26 03:05:08 ET More on Novonesis A/S, Novonesis A/S, etc. Novonesis: Still Too Expensive Historical earnings data for Novonesis A/S Financial information for Novonesis A/S Seeking Alpha’s Quant Rating on Novonesis A/S Historical earning...

Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%. COPENHAGEN, Denmark – February 26, 2025. In the 2024 financial year, Novonesi...

2025-02-21 04:35:00 ET Summary The portfolio generated strong absolute returns in Q4 and 2024, and it outperformed the MSCI AC World Small Mid Index over each period. Q4 performance was driven by strong security selection, where portfolio holdings outperformed in 9 of the 10 secto...